News & Updates
Filter by Specialty:
Olanzapine a favourable alternative to dexamethasone for CINV
Olanzapine administered at a dose of 5 mg was noninferior to dexamethasone and is associated with fewer adverse effects than dexamethasone for chemotherapy-induced nausea and vomiting (CINV), according to data presented at ESMO 2021.
Olanzapine a favourable alternative to dexamethasone for CINV
27 Sep 2021
Ribociclib plus letrozole improves OS in hormone receptor–positive, HER2-negative advanced breast cancer
A combined regimen of ribociclib plus letrozole as first-line treatment provides a statistically significant and clinically meaningful overall survival (OS) benefit vs placebo plus letrozole in postmenopausal patients with hormone receptor–positive and HER2-negative advanced breast cancer (BC), results of the phase III MONALEESA-2 study have shown.
Ribociclib plus letrozole improves OS in hormone receptor–positive, HER2-negative advanced breast cancer
27 Sep 2021
Aggressive hydration averts contrast-induced AKI in STEMI patients undergoing PCI
Perioperative aggressive hydration appears to be better than general hydration at preventing contrast-induced acute kidney injury (AKI) among patients with myocardial infarction with ST-segment elevation (STEMI) undergoing primary percutaneous coronary intervention (PCI), a study has found.
Aggressive hydration averts contrast-induced AKI in STEMI patients undergoing PCI
26 Sep 2021
Educational intervention improves lung function, quality of life, inflammatory profile in asthmatics
An educational intervention for proper inhaled corticosteroid use helps improve lung function, quality of life, and control of inflammation among asthma patients, a recent study has found.